Similar articles for PMID: 21504364

Year	Number of Results
2007	1
2008	4
2009	8
2010	7
2011	9
2012	20
2013	6
2014	10
2015	6
2016	1
2024	0

1

The potential role of CD133 in immune surveillance and apoptosis: a mitochondrial connection?

Zobalova R, Prokopova K, Stantic M, Stapelberg M, Dong LF, Ralph SJ, Akporiaye E, Neuzil J. Zobalova R, et al. Antioxid Redox Signal. 2011 Dec 15;15(12):2989-3002. doi: 10.1089/ars.2010.3785. Epub 2011 Jun 14. Antioxid Redox Signal. 2011. PMID: 21504364 Review.

2

Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53.

Park EK, Lee JC, Park JW, Bang SY, Yi SA, Kim BK, Park JH, Kwon SH, You JS, Nam SW, Cho EJ, Han JW. Park EK, et al. Cell Death Dis. 2015 Nov 5;6(11):e1964. doi: 10.1038/cddis.2015.313. Cell Death Dis. 2015. PMID: 26539911 Free PMC article.

3

Biology and clinical implications of CD133(+) liver cancer stem cells.

Ma S. Ma S. Exp Cell Res. 2013 Jan 15;319(2):126-32. doi: 10.1016/j.yexcr.2012.09.007. Epub 2012 Sep 19. Exp Cell Res. 2013. PMID: 22999864 Review.

4

Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.

Botchkina IL, Rowehl RA, Rivadeneira DE, Karpeh MS Jr, Crawford H, Dufour A, Ju J, Wang Y, Leyfman Y, Botchkina GI. Botchkina IL, et al. Cancer Genomics Proteomics. 2009 Jan-Feb;6(1):19-29. Cancer Genomics Proteomics. 2009. PMID: 19451087 Free article.

5

Targeting CD133 antigen in cancer.

Ferrandina G, Petrillo M, Bonanno G, Scambia G. Ferrandina G, et al. Expert Opin Ther Targets. 2009 Jul;13(7):823-37. doi: 10.1517/14728220903005616. Expert Opin Ther Targets. 2009. PMID: 19530986 Review.

6

CD133 is a marker of bioenergetic stress in human glioma.

Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR Jr, Gillespie GY. Griguer CE, et al. PLoS One. 2008;3(11):e3655. doi: 10.1371/journal.pone.0003655. Epub 2008 Nov 5. PLoS One. 2008. PMID: 18985161 Free PMC article.

7

CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.

Choy W, Nagasawa DT, Trang A, Thill K, Spasic M, Yang I. Choy W, et al. Neurosurg Clin N Am. 2012 Jul;23(3):391-405. doi: 10.1016/j.nec.2012.04.011. Epub 2012 Jun 5. Neurosurg Clin N Am. 2012. PMID: 22748652 Review.

8

Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.

Gambelli F, Sasdelli F, Manini I, Gambarana C, Oliveri G, Miracco C, Sorrentino V. Gambelli F, et al. Cell Biol Int. 2012 Jan;36(1):29-38. doi: 10.1042/CBI20110013. Cell Biol Int. 2012. PMID: 21916848

9

Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.

Bahnassy AA, Fawzy M, El-Wakil M, Zekri AR, Abdel-Sayed A, Sheta M. Bahnassy AA, et al. Transl Res. 2015 Mar;165(3):396-406. doi: 10.1016/j.trsl.2014.07.009. Epub 2014 Aug 7. Transl Res. 2015. PMID: 25168019

10

CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges.

Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D, Kunz-Schughart LA. Grosse-Gehling P, et al. J Pathol. 2013 Feb;229(3):355-78. doi: 10.1002/path.4086. Epub 2012 Nov 20. J Pathol. 2013. PMID: 22899341 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

63 results

Results by year